Real world use of ixekizumab is associated with reductions in concomitant medications among biologic-experienced or biologic-naive patients with psoriasis

被引：0
|
作者：
Wu, Jashin J. [1 ]
Zhu, Baojin [2 ]
Burge, Russel [2 ]
Goldblum, Orin [2 ]
Choong, Casey [2 ]
Edson-Heredia, Emily [2 ]
Amato, David [2 ]
机构：
[1] Dermatol Res & Educ Fdn, Irvine, CA USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
9884
引用
收藏
页码：AB114 / AB114
页数：1
相关论文
共 50 条
  • [21] Extended induction in the True North open-label extension study: Ozanimod efficacy in biologic-naive and biologic-experienced patients
    Dignass, A.
    Sparrow, M.
    Regueiro, M.
    Colombel, J-F
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Vermeire, S.
    Rubin, D. T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 120 - 121
  • [22] Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Ridenour, Terri L.
    Somani, Najwa
    Zhu, Baojin
    Atiya, Bilal
    Lew, Carolyn R.
    Kern, Scott A.
    Zimmerman, Nicole M.
    Murage, Mwangi J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB114 - AB114
  • [23] Comparative efficacy of advanced treatments in biologic-naive or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
    Lu, Xiaoyan
    Jarrett, James
    Sadler, Susannah
    Tan, Min
    Dennis, James
    Jairath, Vipul
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (02) : 330 - 341
  • [24] Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis
    Bagel, Jerry
    Novak, Kristin
    Nelson, Elise
    CUTIS, 2022, 109 (02): : 103 - 109
  • [25] Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 45 - 54
  • [26] Real-world comparison of monotherapy and concomitant medication use with biologic therapies for psoriasis: Ixekizumab versus guselkumab
    Blauvelt, Andrew
    Burge, Russel
    Charbonneau, Bridget
    Malatestinic, William
    Zhu, Baojin
    Wang, Fangyu
    Lockshin, Benjamin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB23 - AB23
  • [27] Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 365 - 371
  • [28] Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
    Kaplan, David L.
    Ung, Brian L.
    Pelletier, Corey
    Udeze, Chuka
    Khilfeh, Ibrahim
    Tian, Marc
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 369 - 377
  • [29] Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    Khilfeh, Ibrahim
    Curtis, Jeffrey R.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 767 - 779
  • [30] Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population
    Pappas D.A.
    Reed G.W.
    Saunders K.
    John A.
    Shewade A.
    Greenberg J.D.
    Kremer J.M.
    Rheumatology and Therapy, 2015, 2 (1) : 85 - 96
12345